ClinicalTrials.gg
Active, not recruitingNCT04821739Updated May 13, 2026

RISE - Study of the AGN1 LOEP SV Kit in Patients With Vertebral Compression Fractures

An interventional study of AGN1 LOEP SV Kit in Vertebral Compression Fracture, Vertebral Compression and Vertebral Fracture, sponsored by AgNovos Healthcare, LLC. Active, not recruiting at 3 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by AgNovos Healthcare, LLC · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Spinal Fractures with a site in Spain — 2 open to participants now, 3 under way, none of them phase 3. Spinal Fractures · Spain.

Started
2021
the only one that year
No phase
5 of 11
1 open now
Registered
8th of 11
by date
Lead sponsor
1 of 11
AgNovos Healthcare, LLC

Among the 11 studies in Spinal Fractures with a site in Spain, this one is the only one that started in 2021, is one of 5 with no phase, and was the 8th registered.

Spinal Fractures

144 studies on the registry are indexed under Spinal Fractures; 24 are open to participants now.

Browse Spinal Fractures studies →

Open to participants now

2 of the 11 studies in Spinal Fractures with a site in Spain are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 18 Spinal Fractures studies recruiting now, 11 (61%) set no upper age limit and 4 (22%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Spinal Fractures with a site in Spain, or all of them as a file.
02

Study summary

This study is a prospective, single-arm, multi-center, European clinical study designed to evaluate the clinical performance and safety of the AGN1 LOEP SV Kit for the treatment of painful VCFs.

Read the detailed description

A maximum of 100 subjects will be treated at up to 10 study sites across Europe. Follow up visits will be conducted at 1 day, 1 month, 3 months, 12 months and 24 months after the procedure.

Study enrollment will occur in three stages:

Stage 1: 5 subjects to evaluate safety at 3 months Stage 2: 30 subjects to evaluate safety at 3 months Stage 3: 100 subjects to evaluate safety and performance at 12 months

03

Conditions studied

  • Vertebral Compression Fracture
  • Vertebral Compression
  • Vertebral Fracture

Browse trials for

Keywords

  • LOEP
  • AGN1
  • RISE
  • Local Osteo-Enhancement Procedure
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is a male or female 50 years of age or older at time of study treatment.
  2. Criterion omitted
  3. Subject has only one (1) acute VCF. Subjects are eligible if they have an asymptomatic healed VCF at any non-target vertebral level.
  4. This VCF meets all of the following criteria:

    1. Fracture due to diagnosed or presumed underlying osteoporosis
    2. VCF from T1 to L5 inclusive
    3. Fracture age ≤6 months at time of treatment
  5. Target VCF shows loss of height in the anterior or middle portion of the vertebral body of not more than 50% based on X-ray at baseline.
  6. Target VCF is acute or persistent (not healed), as demonstrated by T2 weighted STIR MRI, bone scan, CT, serial radiographs, or other imaging demonstrating acuity.
  7. Subject has central pain upon palpation over the spinal process at the target vertebral body.
  8. Subject has failed conservative medical therapy, defined as either having a VAS back pain score of ≥ 70 mm after 24 hours to 6 weeks of conservative care or a VAS back pain score of ≥ 50 mm after 6 weeks of conservative care.
  9. Subject has an Oswestry Disability Index (ODI) score of ≥ 30%.
  10. Subject is capable of giving written to participate in the study.
  11. The subject's willingness, ability, and commitment to participate in screening, treatment, and all follow-up evaluations for the full length of the study has been documented.

Exclusion criteria

Exclusion Criteria:

  1. Target VCF is due to underlying or suspected tumor.
  2. Target VCF is due to high-energy trauma.
  3. Target VCF is diagnosed as an osteonecrotic fracture.
  4. Target VCF has segmental kyphosis of > 30°.
  5. Target VCF is unstable including split or burst fractures.
  6. Subject has had any prior surgical treatment at the target VCF or adjacent vertebral level (above or below VCF).
  7. Subject has neurologic symptoms, deficits, or radiculopathy related to the VCF.
  8. Subject has spinal canal compromise causing clinical manifestations of cord, neural foramen, or nerve root compression at the level to be treated.
  9. Subject has pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis).
  10. Subject has spondylolisthesis > Grade 1 at target vertebral body.
  11. Subject has pain due to any other condition that requires daily narcotic medication.
  12. Subject has severe cardiopulmonary deficiencies.
  13. Subject has a bleeding disorder.
  14. Subject has a (BMI) > 35.
  15. Subject has a history of metabolic bone disease other than osteoporosis (e.g., Paget's disease, renal osteodystrophy, or osteomalacia).
  16. Subject has a history of tuberculosis spondylitis.
  17. Subject has a history of any invasive (except non-melanoma skin cancer), unless treated with curative intent and with no clinical signs or symptoms of the malignancy for five (5) years.
  18. Subject is on oral or parenteral immune-suppressive drugs.
  19. Subject has an active bone infection at target VCF.
  20. Subject has uncontrolled diabetes mellitus, as determined by the judgment of the Investigator.
  21. Subject has severe renal insufficiency defined as an estimated (eGFR) \< 30 mL/min.
  22. Subject has a diagnosed calcium metabolism disorder.
  23. Subject has known allergies to calcium-based bone void fillers.
  24. Subject is pregnant or planning to become pregnant during participation in the study.
  25. In the judgment of the Investigator, the subject is not a good study candidate (e.g., inability to maintain follow-up schedule, comorbidity or poor general physical/mental health, or drug or alcohol abuse issues).
  26. Subject is currently enrolled in another interventional clinical study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Treatment with AGN1 LOEP SV Kit

    VCF is treated with the AGN1 LOEP SV Kit

    Device: AGN1 LOEP SV Kit

Interventions

  • DeviceAGN1 LOEP SV Kit

    The AGN1 LOEP SV Kit is intended for fixation of pathological fractures of the vertebral body using vertebral augmentation.

06

What researchers measure

Primary outcomes

  1. Change in Back Pain from Baseline

    Change in Back Pain at 12 months from Baseline as indicated by Visual Analogue Scale (VAS), measured on a continuous 100 mm line.

    Time frame: 12 months

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Dec 2027, 78 months after the start.

Of 36 interventional studies with no phase under Spinal Fractures, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 70. This study's planned 78 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2021
First posted
Mar 30, 2021
StartActual
May 19, 2021
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2028
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04821739
Lead sponsor
AgNovos Healthcare, LLC
Responsible party
Sponsor
First posted
Mar 30, 2021
Start date
May 19, 2021
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
May 13, 2026

Study contacts

Mohammad Arab Motlagh, MD
principal investigator · Sana Klinikum Offenbach GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion